New bioelectroceutical platform triggers dual cell death, reverses immunosuppression in colorectal cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 18-Nov-2025 00:11 ET (18-Nov-2025 05:11 GMT/UTC)
Scientists from Tianjin University have made a groundbreaking advancement in cancer therapeutics by developing an oral "microbial fuel cell" capsule. This innovative platform, activated by non-invasive ultrasound, mounts a multi-pronged attack within colorectal tumors. It effectively eradicates tumor cells, activates the immune system, and remodels the intestinal microbiota. Animal model studies demonstrated an impressive approximately 90% tumor inhibition rate with no detectable systemic toxicity, establishing a novel paradigm for the treatment of colorectal cancer and other solid tumors.
A new University of Chicago study explores how prolonged exposure to ultraviolet (UV) radiation can trigger inflammation in skin cells through degradation of a key protein called YTHDF2. This protein acts as a gatekeeper in preventing normal skin cells from becoming cancerous. The finding opens the door to develop potential new approaches to skin cancer prevention and treatment.
Scientists at Gladstone Institutes and UC San Francisco (UCSF) have mapped the intricate network of genetic switches that immune cells use to fine-tune levels of FOXP3. Their findings, published in Immunity, have important implications for developing immune therapies and address a long-standing mystery about why this gene behaves differently in humans than in mice.